Viking Global Investors

Viking Global Investors invests at the buyout/lbo, debt - general, early stage vc, later stage vc, pe growth/expansion and seed round stages, with a focus on Agriculture, Business Products and Services (B2B), Consumer Products and Services (B2C), Healthcare Devices and Supplies, Healthcare Technology Systems and Pharmaceuticals and Biotechnology.

Its SEC Form ADV lists $53.5 billion in regulatory assets under management across 15 private funds (Mar 2026).

Viking Global Investors joined 56 recorded rounds in the last two years (14 in the last 12 months), in line with the 55 in the two years before. By year: 6 in 2026, 41 in 2025 and 35 in 2024. Across all 247 recorded rounds, 100 were later-stage, 54 were early-stage and 6 were seed. Viking Global Investors most often invests alongside RA Capital Management (10 shared rounds) and Fidelity Management & Research Company (6 shared rounds). Most recently: Antheia (Series C, Jan 2026) and KidKare (buyout/lbo (add on)† round, Jan 2026).

33 portfolio companies are on record for Viking Global Investors, including Lightmatter, Clip and ID.me. The book leans Drug Discovery (10), Biotechnology (4) and Business/Productivity Software (3).

22 of the 33 carry a recorded valuation and 1 have recorded secondary-market trades, the names a secondary buyer or seller can price.

49 people are on record at Viking Global Investors: 16 principals, 4 managing partners, 3 partners, 2 associates and 24 others. Senior names include David Truetzel (Managing Director), Hans Reuter (Managing Director) and Karim Helmy Ph.D (Managing Director). 49 of them have a verified direct contact on file.